July 24th 2019
Richard T. Penson, MD, MRCP, discusses novel strategies with PARP inhibitors and the use of biomarkers to create more personalized treatments for patients with platinum-sensitive ovarian cancer.
July 19th 2019
Keerthi Gogineni, MD, MSHP, discusses several trials in the breast cancer field, specifically looking at de-escalation therapies.
Jubilee Brown, MD, discusses the importance of molecular testing immediately after an ovarian cancer diagnosis and how molecular testing will shape the field of ovarian cancer.
July 17th 2019
Thomas Herzog, MD, discusses recent changes in the ovarian cancer landscape, specifically PARP inhibitors and the optimal use of bevacizumab.
July 15th 2019
Alain Borczuk, MD, discusses the recent advancements in lung cancer treatment, the evolving field, and the future potential for liquid biopsies.
July 14th 2019
Justin F. Gainor, MD, highlights the evolving paradigm for the use of immunotherapy in the treatment of patients with unresectable locally advanced non–small cell lung cancer.
July 12th 2019
Christopher Sweeney, MBBS, discusses the results of the ENZAMET trial and the next steps for researching the efficacy of enzalutamide in the treatment of patients with metastatic hormone-sensitive prostate cancer.
Robert Dreicer, MD, highlights the current state of immunotherapy in urothelial cancer and ongoing research poised to offer more information on how to broaden its effects.
July 11th 2019
Inga T. Lennes, MD, MBA, MPH, discusses the recommended screening protocol for patients at risk for lung cancer, maintaining patients post-screening, and how physicians can best assist this patient population.
July 10th 2019
Mary Jo J. Fidler, MD, discusses intriguing data with pemetrexed in patients with nonsquamous non–small cell lung cancer.
July 3rd 2019
Robert L. Redner, MD, highlights some of the newer available agents in acute myeloid leukemia and ongoing studies that could impact clinical practice.
Robert C. Doebele, MD, PhD, discusses a retrospective trial comparing the efficacy of entrectinib with crizotinib in the treatment of patients with ROS1-positive non–small cell lung cancer.
Andrew J. Cowan, MD, discussed pivotal trials in multiple myeloma and potential for new treatments in the future.
July 1st 2019
Kim Chi, MD, discusses how the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy could be a new standard of care for patients with metastatic castration-sensitive prostate cancer.
June 27th 2019
Switch maintenance treatment with pembrolizumab improved progression-free survival in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy.
June 26th 2019
Hossein Borghaei, MD, highlights long-term single-agent pembrolizumab (Keytruda) data and the overall state of immunotherapy in non–small cell lung cancer, as well as the prospect of making clinical trial eligibility less restrictive.
Jennifer Woyach, MD, discusses the 3-year follow-up from the single-arm study of the combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) showcase the efficacy of the regimen in both patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia and the future of treatment in the space.
June 25th 2019
Ross Mudgway, discusses the importance of considering surgery for patients with stage IV HER2-positive breast cancer and addresses disparities in healthcare among different social groups.
June 20th 2019
Jennifer R. Brown, MD, PhD, highlights the new and upcoming research regarding acalabrutinib in the field of chronic lymphocytic leukemia.
February 21st 2017
Concern over the cost of cancer drugs nearly doubled among oncology professionals from 2015 to 2016, jumping from 45% to 83%.